Revenue and net profit saw strong year-over-year growth in both standalone and consolidated results for Q1 FY27, driven by robust performance in Life Science and Performance Chemicals. Appointment of an experienced Independent Director and a one-time gain in employee expenses last quarter were notable developments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.